PE20011314A1 - DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA - Google Patents

DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA

Info

Publication number
PE20011314A1
PE20011314A1 PE2001000442A PE2001000442A PE20011314A1 PE 20011314 A1 PE20011314 A1 PE 20011314A1 PE 2001000442 A PE2001000442 A PE 2001000442A PE 2001000442 A PE2001000442 A PE 2001000442A PE 20011314 A1 PE20011314 A1 PE 20011314A1
Authority
PE
Peru
Prior art keywords
phenyl
carbamimidoyl
glycin
derivatives
ixa
Prior art date
Application number
PE2001000442A
Other languages
English (en)
Inventor
Leo Alig
Kurt Hilpert
Katrin Groebke Zbinden
Ulrike Obst
Hans Peter Wessel
Holger Kuehne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20011314A1 publication Critical patent/PE20011314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA DE FORMULA I DONDE R1 ES ALQUILO; R2 ES H, HIDROXIALCOXILO, ALCOXICARBONILOXI, ALCOXILO, ENTRE OTROS; R3 ES H, ALCOXILO, HETEROCICLOALQUILOXILO; R4 ES H, ESTER; R5 ES H, HIDROXILO, ALCOXICARBONILO, HALOGENOALCOXICARBONILO, ENTRE OTROS; X ES F, Cl, Br. SON COMPUESTOS PREFERIDOS ESTER ETILICO DEL ACIDO (RS)-(4-CARBAMIMIDOIL-FENILAMINO)-3,5-DIETOXI-2-FLUORO-FENIL-ACETICO, ACIDO (RS)-(4-CARBAMIMIDOIL-FENILAMINO)-(2-FLUORO-3,5-DIMETOXI-FENIL)-ACETICO, ESTER ETILICO DEL ACIDO (RS)-(4-CARBAMIMIDOIL-FENILAMINO)-(2-FLUORO-3,5-DIMETOXI-FENIL)-ACETICO. LOS DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA SON INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA Y SON UTILES PARA LA PREVENCION Y TRATAMIENTO DE TROMBOSIS, APOPLEJIA, INFARTO CARDIACO
PE2001000442A 2000-05-23 2001-05-17 DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA PE20011314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110881 2000-05-23

Publications (1)

Publication Number Publication Date
PE20011314A1 true PE20011314A1 (es) 2002-01-04

Family

ID=8168800

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000442A PE20011314A1 (es) 2000-05-23 2001-05-17 DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA

Country Status (23)

Country Link
US (1) US6548694B2 (es)
EP (1) EP1289939A1 (es)
JP (1) JP3842132B2 (es)
KR (1) KR100569517B1 (es)
CN (1) CN1305839C (es)
AR (1) AR028596A1 (es)
AU (2) AU2001281774B2 (es)
BR (1) BR0110998A (es)
CA (1) CA2408602C (es)
EC (1) ECSP024360A (es)
HU (1) HUP0302073A2 (es)
IL (1) IL152581A0 (es)
MA (1) MA26905A1 (es)
MX (1) MXPA02011466A (es)
NO (1) NO20025590D0 (es)
NZ (1) NZ522412A (es)
PE (1) PE20011314A1 (es)
PL (1) PL361355A1 (es)
RU (1) RU2268257C2 (es)
UY (1) UY26721A1 (es)
WO (1) WO2001090051A1 (es)
YU (1) YU83602A (es)
ZA (1) ZA200208899B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100473966B1 (ko) * 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체
DE10300049A1 (de) * 2003-01-03 2004-07-15 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Faktor VIIa inhibieren
US6642386B2 (en) * 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
GB0211931D0 (en) * 2002-05-23 2002-07-03 Univ Liverpool Methods & device utilizing adsorption of molecules at a surface or interface
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
JP2006517589A (ja) 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
EP1594505A4 (en) 2003-02-11 2008-08-13 Bristol Myers Squibb Co PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7917130B1 (en) 2003-03-21 2011-03-29 Stratosaudio, Inc. Broadcast response method and system
US7776804B2 (en) * 2005-03-16 2010-08-17 The Lubrizol Corporation Viscosity improver compositions providing improved low temperature characteristics to lubricating oil
US7056932B2 (en) * 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
JP4478157B2 (ja) * 2004-10-13 2010-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヒドラジド誘導体
CA2584485C (en) * 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TW200637843A (en) 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
DE602006011752D1 (de) * 2005-06-24 2010-03-04 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
EP2000465B1 (en) * 2006-03-24 2010-12-15 Eisai R&D Management Co., Ltd. Triazolone derivative
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
EP1967522A1 (en) * 2007-03-07 2008-09-10 Novo Nordisk A/S New blood coagulation factor inhibitors
US7807690B2 (en) * 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
US8631448B2 (en) 2007-12-14 2014-01-14 Stratosaudio, Inc. Systems and methods for scheduling interactive media and events
AU2009262252B2 (en) * 2008-06-26 2013-05-02 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ708314A (en) 2009-03-18 2017-08-25 Resverlogix Corp Quinazolinones for use as anticancer agents
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
CN102887836B (zh) * 2011-07-18 2014-03-26 西南大学 L-苯甘氨酸衍生物及其应用
GB201118876D0 (en) * 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
CN111072562B (zh) * 2019-11-07 2021-12-07 中山大学 一种四氢异喹啉衍生物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0921116T3 (da) 1997-12-04 2003-10-06 Hoffmann La Roche N-(4-carbamimido-phenyl)-glycinamidderivater
EP1078917A4 (en) 1998-02-17 2002-11-06 Ono Pharmaceutical Co AMIDINO DERIVATIVES FOR USE AS ACTIVE INGREDIENTS AND MEDICINES CONTAINING THEM
KR100473966B1 (ko) * 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체

Also Published As

Publication number Publication date
HUP0302073A2 (hu) 2003-09-29
RU2268257C2 (ru) 2006-01-20
NO20025590L (no) 2002-11-21
ZA200208899B (en) 2004-02-19
AU8177401A (en) 2001-12-03
AU2001281774B2 (en) 2005-03-10
JP3842132B2 (ja) 2006-11-08
YU83602A (sh) 2006-05-25
AR028596A1 (es) 2003-05-14
US6548694B2 (en) 2003-04-15
KR20030007678A (ko) 2003-01-23
PL361355A1 (en) 2004-10-04
NO20025590D0 (no) 2002-11-21
JP2003534311A (ja) 2003-11-18
US20020004608A1 (en) 2002-01-10
BR0110998A (pt) 2003-04-08
ECSP024360A (es) 2003-03-31
UY26721A1 (es) 2001-12-28
CN1430599A (zh) 2003-07-16
CN1305839C (zh) 2007-03-21
EP1289939A1 (en) 2003-03-12
WO2001090051A1 (en) 2001-11-29
CA2408602A1 (en) 2001-11-29
KR100569517B1 (ko) 2006-04-07
NZ522412A (en) 2004-05-28
CA2408602C (en) 2008-01-08
MXPA02011466A (es) 2003-04-25
IL152581A0 (en) 2003-05-29
MA26905A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
EA200100457A1 (ru) Способ получения циталопрама
PE20020058A1 (es) Derivados de piperidina tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
NO20021229D0 (no) Benzamider og lignende inhibitorer for faktor Xa
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
AR039226A2 (es) Compuestos utiles como intermediarios de preparacion y procedimientos
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
GB2303851A (en) Pharmaceutical diketopiperazine compounds
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
NI200400073A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
UY25888A1 (es) Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias
ES2202156T3 (es) Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
TR200102043T2 (tr) Hücre yapışma önleyicileri olarak monosakkaritlerin 2,3-O-izopropiliden türevleri.
MY133333A (en) New salts
WO2001070693A3 (en) Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
PE20020339A1 (es) Derivados de pirrolidin como inhibidores de las metaloproteasas
AR019438A1 (es) Compuesto derivado de piperazina, usos del mismo y metodos para su fabricacion
DK1226819T3 (da) Inhibitor for 20-HETE-producerende enzym
PE20020484A1 (es) Derivados de pirimidina como inhibidores de la enzima conversor de endotelina
AR038480A1 (es) Derivados de fenilglicina solubles en agua
UY27425A1 (es) Nuevos derivados de ácido mandelicoy su uso como inhibidores de trombina
ATE265428T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
DK1042297T3 (da) Carboxylsyresubstituerede heterocykliske forbindelser som metalloproteinaseinhibitorer
WO2001070682A3 (en) Carbocyclic side chain containing metalloprotease inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed